Hello,
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:
- Analysts lay out why Humana's under-valued;
- Getting COVID-19 doesn't guarantee protection from reinfection;
- Experts say the variant first spotted in Brazil is developing mutations that could make vaccines less effective.
If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @lydiaramsey125. Let's get to it…
Humana CEO Bruce Broussard
Reuters
Reuters
4 reasons why health insurer Humana is 'significantly under-valued' and could pop, according to one Wall Street firm
- Analysts at Wall Street firm Stephens are betting big on health insurance giant Humana.
- Humana has built primary-care and home healthcare businesses that are undervalued, analysts said.
- Humana's main market, Medicare Advantage, is likely to remain stable during the Biden administration.
Here are the 4 reasons why it's undervalued>>
Members of U.S. Air Force prepare to receive the first round of the Moderna COVID-19 vaccine at Osan Air Base on December 29, 2020 in Pyeongtaek, South Kore
United States Forces Korea/Getty Images
United States Forces Korea/Getty Images
Getting COVID-19 doesn't always protect young people from reinfection, study finds
- Getting COVID-19 doesn't guarantee protection from reinfection.
- In one study, around 10% of Marine recruits who previously had COVID-19 were reinfected.
- Those who had antibodies were about five times less likely to get infected than those who didn't have them.
A COVID-19 patient is rushed into a hospital in Brasilia, Brazil on January 11, 2021.
Xinhua/Lucio Tavora via Getty
Xinhua/Lucio Tavora via Getty
The coronavirus variant first found in Brazil is developing worrying new mutations that could make vaccines less effective, experts say
- Brazil's top public-health body is warning about the P.1 coronavirus variant, first found in Brazil.
- Some mutations may make the shot more resistant to vaccines, Fiocruz said.
- Another study published Wednesday indicated P.1 could reinfect people who previously had COVID-19.
More stories we're reading:
- UnitedHealth Group's membership grew, and it posted a profit for the first-quarter of 2021 (The Wall Street Journal)
- Johnson & Johnson asked other drugmakers to help it study blood-clot risks, and Moderna and Pfizer declined, report says (Insider)
- Vaccines that protect against many coronaviruses could prevent future pandemics (Science)
- Most COVID-19 ICU patients in Brazil are now under 40 years old. Experts think the spread of a variant is to blame. (Insider)
- Lydia
Read the original article on Business Insider